



YOU'RE INVITED:

T-CELL LYMPHOMA WEBINAR SERIES

How Do I Sequence Treatment?

A Case-based Approach

AGENDA (1 hr):

45 mins **"How do I sequence treatment?"**

Presentation by Dr O'Connor

15 mins **Live Q&A**

*Japanese/Spanish translation available

OVERVIEW:

To discuss and illustrate with case examples and supporting key data, what are the determining factors in a patient's profile that aid the clinician's decision in optimizing sequential therapy involving novel agents (eg. pralatrexate, HDAC inhibitors, brentuximab, mogamulizumab) and conventional chemotherapy.



SPEAKER:

Dr. Owen O'Connor, MD, PhD

University of Virginia Cancer Center, U.S.A

Owen A. O'Connor, MD, Ph.D., an international authority in lymphoma and drug development, with more than 25 years of experience in academic medicine. Dr. O'Connor is widely recognized for his contributions to the field, having pioneered the development of several first-in-class drugs like belinostat and vorinostat, and co-invented and led the international development of pralatrexate, which became the first drug approved for patients with relapsed or refractory peripheral T-cell lymphoma, now approved in over 35 countries around the world. Dr. O'Connor has published over 200 articles in peer-reviewed journals, books and book chapters and reviews on the management of lymphoma. Dr. O'Connor has and presently serves on a number of Scientific Advisory Boards, including the Lymphoma Research Foundation and the Leukemia and Lymphoma Society.

He has received countless awards for his research, including being a recipient of the American Cancer Society Research Professorship, the most prestigious honor bestowed by the Society.

DATE & TIME:

Webinar 1*:

20 April (Tues)

7-8 pm

OR

Webinar 2:

22 April (Thu)

8-9 am

[CLICK HERE](#)

OR

**SCAN FOR
REGISTRATION**

